

## Flavonoids with Bradykinin Antagonistic Effects from *Scutellariae Radix*

Hye Sook Yun-Choi, Kyung Sook Yoo, Sung Hyun Chung,\*

Hyun Sook Yang,\* Jin Jae Choi\* and Young Joo Kim\*

Natural Products Research Institute, Seoul National University, Seoul 110-460

and \*College of Pharmacy, Kyunghee University, Seoul 130-701, Korea

**Abstract**—Seven flavonoid components were isolated from fr. C of *Scutellariae radix* which showed antagonistic effects against bradykinin(BK). The results indicated that two oxygen functions (either -OH or -OCH<sub>3</sub>) at 2'- and 6'-positions and/or an oxygen function at 6-position of flavone seemed to be favored for the BK inhibitory activities. Skullcapflavone-II(IV) which contains 6-OCH<sub>3</sub>, 2'-OH and 6'-OCH<sub>3</sub> in the structure was the most active among the flavones tested.

**Keywords**—*Scutellariae radix* • bradykinin antagonistic • oroxylin A • wogonin • skullcapflavone-I • skullcapflavone-II • chrysin • 5, 2', 6' -trihydroxy-7, 8-dimethoxyflavone • baicalein

Bradykinin (BK, Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg) is a potent inflammatory peptide whose generation in tissues and body fluids elicits numerous responses including vasodilation, edema, smooth muscle spasm, as well as pain and hyperalgesia. There are substantial evidences that BK and related kinins, such as kallidin, contribute to the inflammatory responses in acute and chronic diseases including allergic reactions, arthritis, asthma, sepsis, viral rhinitis, and inflammatory bowel diseases. BK is also a potent algescic agent, comparable in potency to substance P, and many times more potent than serotonin, histamine, or acetylcholine. In addition to its algescic and proinflammatory actions, BK exhibits a vasodilator action. And because of its ability to lower blood pressure, BK has been implicated in the pathogenesis of several shock syndromes, particularly septic or endotoxic shock.<sup>1-4)</sup> Kinin receptors were originally classified according to

the relative potencies of agonists in isolated vascular smooth muscle preparations and divided into two classes, B<sub>1</sub> and B<sub>2</sub>, although there are recent evidences for the third BK receptor which may not fall into the typical B<sub>1</sub> or B<sub>2</sub> receptor classification.<sup>5)</sup> B<sub>1</sub> receptors were better characterized until the discovery of the competitive B<sub>2</sub> receptor antagonists in 1985, however, B<sub>2</sub> receptors are far more ubiquitous than B<sub>1</sub> receptors and mediate most physiological effects of BK. Since the report by Stewart and Vavrek that substitution with D-Phe for L-Pro in position 7 of the BK sequence provided the ability to inhibit B<sub>2</sub> receptor-mediated effects, hundreds of analogues have been synthesized, and the structure-activity relationships of these antagonists were analysed.<sup>2,3,6,7)</sup> With the aid of the specific antagonists of BK, the physiological, pharmacological, and pathological roles of BK are being exploited in various biological

systems. Antagonists of this type block the majority of the biological effects of BK that are mediated by B<sub>2</sub> receptors and, in primary studies, produced encouraging results in the relief of cold symptoms caused by the rhinovirus, in the suppression of pain from burns, and in the treatment of allergic asthma.<sup>8-10</sup> However, the BK antagonists with the BK analogous peptide structure, unfortunately, have very short half-lives *in vivo*. The availability of a stable and specific non-peptide BK antagonist could provide a possible new form of therapeutic potential.

Scutellariae Radix (the root of *Scutellaria baicalensis* Georgi, Labiatae) have been used for the treatment of inflammatory diseases, suppurative dermatitis, allergic diseases, fever *etc.* in Oriental traditional medicine. Various biological activities including antithrombotic, anti-allergic, anti-inflammatory activities were reported with the solvent extracts or with the constituents.<sup>11-13</sup> As regards the constituents, flavonoids are the major components reported and about 40 flavonoids (either in free form or as glycosides) have been identified from this plant so far.<sup>12,14,15</sup>

In the previous paper, we reported the fr. C (the flavonoid and neutral component-containing ether soluble fraction) prepared from the EtOAc extract of Scutellariae Radix showed antagonistic effects against bradykinin (BK) *in vitro* and *in vivo*.<sup>16</sup> Fr. C inhibited the BK-induced contractions in rat ileum and uterus. Oral administration of fr. C reduced the plasma extravasation induced by intradermal injection of BK in mice, decreased the numbers of writhing syndrome induced by the *i.p.* injection of 0.7% acetic acid and lowered the mortality caused by endotoxic shock.<sup>16</sup> The present paper deals with a study on the antagonistic effects against BK with various flavonoids obtained from Scutellariae Radix.

## Experimental

### General experimental procedure

Melting point was determined on a Mitamura-Riken apparatus and are uncorrected. <sup>1</sup>H-NMR spectra were obtained on a Varian FT-80A (80MHz) using TMS as an internal standard. MS spectra were determined on a Hewlett-Packard 5985B GC/MS System equipped with a direct inlet system.

### Plant material and reagents

Scutellariae radix was purchased from a local crude drug market and identified as *Scutellaria baicalensis* Georgi by Prof. Hyung Joon Chi of Natural Products Research Institute, Seoul National University. BK (Bradykinin acetate salt) was purchased from Sigma Chemical Company.

### Extraction and fractionation

The dried and chopped Scutellariae radix was extracted and fractionated as described in the previous paper.<sup>16</sup> Fr. C was chromatographed on a silica gel column eluting with CHCl<sub>3</sub> with gradually increasing concentration of MeOH affording seven flavonoids as shown in Scheme I. Compounds I, II, III, IV, V, VI and VII were directly compared with the authentic samples (mixed mp and TLC) and the spectral data were compared with the reported data.

### Oroxilin A(I)

mp 200~201° (from benzene), MS, *m/z* 284 (M<sup>+</sup>), 269(M<sup>+</sup>-CH<sub>3</sub>), 241(M<sup>+</sup>-CH<sub>3</sub>CO), 167, 139; <sup>1</sup>H-NMR(d<sub>6</sub>-DMSO) δ: 3.76(3H, s, OCH<sub>3</sub>), 6.62(1H, s, C<sub>3</sub>-H), 6.93(1H, s, C<sub>8</sub>-H), 7.5~8.2(5H, m, C<sub>2'-6'</sub>-H), 12.89(1H, s, C<sub>5</sub>-OH).<sup>17</sup>

### Wogonin(II)

mp 207~209°(from mixture of EtOAc and CHCl<sub>3</sub>), MS, *m/z* 284(M<sup>+</sup>), 269(M<sup>+</sup>-CH<sub>3</sub>), 241(M<sup>+</sup>-CH<sub>3</sub>CO), 167, 139; <sup>1</sup>H-NMR(d<sub>6</sub>-DMSO) δ: 3.85(3H, s, OCH<sub>3</sub>), 6.31(1H, s, C<sub>3</sub>-H),

6.96(1H, s, C<sub>6</sub>-H), 7.4~8.2(5H, m, C<sub>2'</sub>-<sub>6'</sub>-H), 10.72(1H, brs, C<sub>7</sub>-OH), 12.47(1H, s, C<sub>5</sub>-OH).<sup>17)</sup>

#### Skullcapflavone-I(III)

mp 254~255°(from benzene), MS, *m/z* 314 (M<sup>+</sup>), 299(M<sup>+</sup>-CH<sub>3</sub>), 181, 153; <sup>1</sup>H-NMR(d<sub>6</sub>-DMSO) δ: 3.82, 3.91(3H each, s, 2×OCH<sub>3</sub>), 6.58(1H, s, C<sub>3</sub>-H), 7.12(1H, s, C<sub>6</sub>-H), 6.9~7.9(4H, m, C<sub>3'</sub>-<sub>6'</sub>-H) 10.82(1H, s, C<sub>2</sub>-OH), 12.67(1H, s, C<sub>5</sub>-OH).<sup>17,19)</sup>

#### Skullcapflavone-II(IV)

mp 180~181°(from benzene), MS, *m/z* 374 (M<sup>+</sup>), 359(M<sup>+</sup>-CH<sub>3</sub>), 211, 183; <sup>1</sup>H-NMR(d<sub>6</sub>-DMSO) δ: 3.73, 3.77, 3.80, 3.98(3H each, s, 4×OCH<sub>3</sub>), 6.32(1H, s, C<sub>3</sub>-H), 6.60(2H, d, *J*=8.5Hz, C<sub>3'</sub> or C<sub>5'</sub>-H), 7.30(1H, t, *J*=8.5Hz, C<sub>4</sub>-H), 10.10(1H, s, C<sub>2</sub>-OH), 12.50(1H, s, C<sub>5</sub>-OH).<sup>17)</sup>

#### Chrysin(V)

mp 277~278°(from benzene), MS, *m/z* 254 (M<sup>+</sup>), 152, 124; <sup>1</sup>H-NMR(d<sub>6</sub>-DMSO) δ: 6.21(1H, d, *J*=2.0Hz, C<sub>6</sub>-H), 6.50(1H, d, *J*=2.0 Hz, C<sub>8</sub>-H), 6.92(1H, s, C<sub>3</sub>-H), 7.4~8.2(5H, m, C<sub>2'</sub>-<sub>6'</sub>-H), 10.83(1H, s, C<sub>7</sub>-OH), 12.79(1H, s, C<sub>5</sub>-OH).<sup>18)</sup>

#### 5, 2', 6'-Trihydroxy-7, 8-dimethoxyflavone(VI)

mp 234~237°(from EtOAc), MS, *m/z* 330 (M<sup>+</sup>), 315(M<sup>+</sup>-CH<sub>3</sub>), 181, 153; <sup>1</sup>H-NMR(d<sub>6</sub>-DMSO) δ: 3.72, 3.90(3H each, s, 2×OCH<sub>3</sub>), 6.26(1H, s, C<sub>3</sub>-H), 6.43(2H, d, *J*=8.1Hz, C<sub>3'</sub> or C<sub>5'</sub>-H), 6.58(1H, s, C<sub>6</sub>-H), 7.12(1H, t, *J*=8.1Hz, C<sub>4</sub>-H), 9.86(2H, s, C<sub>2</sub> or C<sub>6</sub>-OH), 12.70(1H, s, C<sub>5</sub>-OH).<sup>14)</sup>

#### Baicalein(VII)

mp 264~265°(from EtOH), MS, *m/z* 270 (M<sup>+</sup>), 168, 140; <sup>1</sup>H-NMR(d<sub>6</sub>-DMSO) δ: 6.63(1H, s, C<sub>3</sub>-H), 6.94(1H, s, C<sub>8</sub>-H), 7.5~8.2(5H, m, C<sub>2'</sub>-<sub>6'</sub>-H), 12.43(1H, s, C<sub>5</sub>-OH).<sup>17)</sup>

#### BK-induced contraction in the isolated ileum

Terminal ileum was isolated from male rats

(Sprague-Dawley, 150~200g) and 2~3cm segment of ileum was suspended in 10ml tissue bath filled with modified Kreb's solution (composition, g/l; KH<sub>2</sub>PO<sub>4</sub> 0.16, KCl 0.35, CaCl<sub>2</sub> 0.25, MgSO<sub>4</sub>·7H<sub>2</sub>O 0.29, NaCl 6.9, NaHCO<sub>3</sub> 2.1, glucose 1.98) at 36°C and bubbled with 95% O<sub>2</sub>-5% CO<sub>2</sub>. After resting period of about 60 min, isotonic contractions were measured under a resting load of 1g and recorded on a kymograph. 0.1ml of test sample solution was added to the bath 1 min. prior to BK and the effect of the test compound was evaluated comparing with the contraction induced by BK alone.

#### BK-induced contraction in the isolated uterus

Uterine preparations were obtained from virgin rats (Sprague-Dawley, 150~200g) treated with diethyl stilbesterol (0.1mg/ml ethanol/kg, s.c.) 24hr before the experiments. An uterine strip was suspended in 10ml organ bath containing modified De Jalon's solution (composition, g/l; NaCl 9.0, KCl 0.42, CaCl<sub>2</sub> 0.045, glucose 0.5, NaHCO<sub>3</sub> 0.5, MgCl<sub>2</sub> 0.005) at 31°C and bubbled with 95% O<sub>2</sub>-5% CO<sub>2</sub>. And the tests were performed as with isolated ileum.

## Results and Discussion

For the purpose of separating BK antagonistic components, fr. C, the active fraction, was subjected to a silica gel column chromatography affording seven flavonoids(I, II, III, IV, V, VI, and VII). The authors extracted several batches of *Scutellariae radix* (*Scutellariae radix* either cultivated in Korea or imported from China are marketed in the crude drug market in Seoul) to secure the various flavonoid components reported. I, II and VII could be obtained from all the batches extracted. The contents of III, IV, V and VI were variable and could not even be detected from some of the batches. The results of extraction, fractionation and separation



the direct comparison of the mixed mp, TLC *etc.* with the authentic samples obtained from M. Takido of Nihon University in Japan.

The antagonistic effects of each flavonoids against BK were evaluated with the use of rat ileum and rat uterus and the results are summarized in Table I. The existence of at least two types of kinin receptors have been proposed and the B<sub>1</sub> receptor is thought to be induced by *de novo* synthesis. The BK-induced contraction of rat uterus is thought to be mediated by B<sub>2</sub> receptor, while rat isolated ileum contains both B<sub>1</sub> and B<sub>2</sub> receptors. The majority of actions of kinins were assumed to be mediated via B<sub>2</sub> receptors and the stimulation of B<sub>2</sub> receptor is associated with various pathophysiological conditions *e.g.* plasma extravasation, nociceptive stimulation *etc.* In isolated ileum, all of the seven flavonoids showed inhibitory effects against BK. At the concentration of 40 µg/ml, **II**, **IV**, **VI** and **VII** showed 76%, 93%, 52% and 42% inhibition respectively and **II** and **IV** were observed to give more than 50% inhibition at the concentration of 20 µg/ml. At isolated uterus, **IV** was most antagonistic against BK among the seven flavonoids showing 90% inhibition at 40 µg/ml and 53% at 20 µg/ml. **I**, **VI** and **VII** were also mild antagonistic (34%, 37% and 32% respectively at 40 µg/ml) against BK. The results from the limited number of *Scutellariae* flavonoids indicated that the antagonistic effect at the B<sub>2</sub> receptor is favored by the two oxygen functions at R<sub>4</sub> and R<sub>5</sub> (2'- and 6'-positions of flavonoid) as in the case of **IV** and **VI**. An oxygen function at R<sub>1</sub> (6-position of flavonoid) also seemed to be preferred for the B<sub>2</sub> antagonistic effect (**I** and **VII** vs **V**). The oxygen functions at R<sub>1</sub> and two oxygen functions at both R<sub>4</sub> and R<sub>5</sub> seemed to contribute to the concentration of electron density at the oxygen of C=O by either interfering the hydrogen bonding between C=O and C<sub>5</sub>-OH or by

resonance.

## Conclusion

Seven flavonoid components were separated from fr. C of *Scutellariae radix*. The antagonistic effects against BK B<sub>2</sub> receptor seemed to be favored by an oxygen function (either -OH or -OCH<sub>3</sub>) at 6- and/or two oxygen functions at 2'- and 6'- of flavone both of which contribute to the concentration of electron density at the oxygen of C=O. Skullcapflavone-II (**IV**) which contains 6-OCH<sub>3</sub>, 2'-OH and 6'-OCH<sub>3</sub> in the structure was the most active among the *Scutellariae* flavonoids tested.

**Acknowledgments**—The authors thank Dr. H.J. Chi for the identification of the roots of *S. baicalensis* and Dr. M. Takido of Nihon University, Japan for the authentic flavonoids. The authors also express their appreciation to the Korea Science and Engineering Foundation for financial support (Project number: 901-0302-002-2)

⟨Received Sep. 9, 1992:⟩

Accepted Oct. 1, 1992⟩

## Literature Cited

- Garrison, J.C.: Chapter 23 Histamine, Bradykinin, 5-Hydroxytryptamine, and their Antagonists, *The Pharmacological Basis of Therapeutics*, A.G. Gilman *et al.* ed., 8th ed., p.575, MacMillan Publishing Comp. (1991).
- Burch, R.M., Farmer, S.C. and Steranka, L.R.: *Med. Res. Rev.* **10**, 237 (1990).
- Bathon, J.M. and Pround, D.: *Annu. Rev. Pharmacol. Toxicol.* **31**, 129 (1991).
- Farmer, S.G. and Burch, R.M.: *Annu. Rev. Pharmacol. Toxicol.* **32**, 511 (1992).
- Regoli, D. and Barabe, J.: *Pharmacol. Rev.* **32**, 1 (1980).
- Vavrek, R.J. and Stewart, J.M.: *Peptides* **6**, 161 (1985).

7. Steranka, L.R., Farmer, S.G. and Burch, R.M.: *FASEB J.* 3, 2019 (1989).
8. Schachter, M., Uchida, Y., Longridge, D.J., Labedz, T., Whalley, E.T., Vavrek, R.J. and Stewart, J.M.: *Br. J. Pharmacol.* 92, 851 (1987).
9. Griesbacher, T. and Lembeck, F.: *Br. J. Pharmacol.* 92, 333 (1987).
10. Enna, S.J. and Steranka, L.R.: *Tips* 10, 387 (1989).
11. Kubo, M., Matsuda, H., Tani, T., Arichi, S., Kimura, Y. and Okuda, H.: *Chem. Pharm. Bull.* 33, 2411 (1985).
12. Kimura, Y., Okuda, H., Taira, Z., Shoji, N., Takemoto, T. and Arichi, S.: *Planta Med.* 51, 290 (1984).
13. Kubo, M., Matsuda, H., Kimura, Y., Okuda, H. and Arichi, S.: *Chem. Pharm. Bull.* 32, 5051 (1984).
14. Tomimori, T., Miyaichi, Y., Imoto, Y., Kizu, H. and Suzuki, C.: *Yakugaku Zasshi* 104, 529 (1984).
15. Takagi, S., Yamaki, M. and Inoue, K.: *Phytochemistry* 20, 2443 (1981).
16. Chung, S.H., Choi, J.J., Yoo, K.S. and Yun-Choi, H.S.: *Kor. J. Pharmacogn.* 22, 192 (1991).
17. Takido, M., Aimi, M., Takahashi, S., Yamanoouchi, S., Torii, H. and Dohi, S.: *Yakugaku Zasshi* 95, 108 (1975).
18. *Aldrich Library of NMR Spectra*, Vol. 1, 98A.
19. Iinuma, M. and Matsura, S.: *Yakugaku Zasshi* 99, 657 (1979).